Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. CRISPR Therapeutics AG's forward rate of return for was %.
The historical rank and industry rank for CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % or its related term are showing as below:
LTS:0VRQ's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 1.7 * Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
CRISPR Therapeutics AG (LTS:0VRQ) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
CRISPR Therapeutics AG Forward Rate of Return (Yacktman) % Related Terms
CRISPR Therapeutics AG Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Forward Rate of Return (Yacktman) % Chart
LTS:0VRQ vs LGND, DFTX, XENE: Forward Rate of Return (Yacktman) % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Forward Rate of Return (Yacktman) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % falls into.
CRISPR Therapeutics AG Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of % mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Forward Rate of Return (Yacktman) % of % as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 178 companies in the Biotechnology industry.
Is CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % too high?
CRISPR Therapeutics AG's current Forward Rate of Return (Yacktman) % is %. Based on the distribution chart, CRISPR Therapeutics AG ranks #999999 out of 178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Forward Rate of Return (Yacktman) % compare to LGND and DFTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 178 companies for Forward Rate of Return (Yacktman) %. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Biotechnology company?
The median Forward Rate of Return (Yacktman) % among Biotechnology companies is 1.70, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Forward Rate of Return (Yacktman) % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Forward Rate of Return (Yacktman) % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $58.33 — trading 926.9% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is %. CRISPR Therapeutics AG's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Forward Rate of Return (Yacktman) % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $58.33 is trading 926.9% above its estimated GF Value™ of $5.68.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
Forward Rate of Return (Yacktman) %: %
GF Value™: $5.68 vs. price of $58.33 (926.9% above fair value)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CRISPR Therapeutics AG is a Swiss biopharmaceutical company focused on developing gene-editing medicines based on CRISPR/Cas9 technology, which enables precise modification of genomic DNA. Its lead product, Casgevy, was developed with Vertex Pharmaceuticals and is approved for sickle cell disease and transfusion-dependent beta-thalassemia. The company also advances programs in immuno-oncology, cardiovascular disease, and a stem-cell-derived therapy for type 1 diabetes, alongside in vivo editing approaches. CRISPR Therapeutics conducts research and development across sites in Switzerland, the United States, and Canada, and generates revenue through collaboration and licensing agreements, including with Vertex, as well as potential product sales. Its pipeline spans both ex vivo cell therapies and in vivo treatments targeting genetically defined diseases.
37GF Score
Get the complete analysis for LTS:0VRQ
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
